The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors

被引：0
|
作者：
Kamaraju, Sailaja
Fowler, Amy
Chaudhary, Lubna N.
Burkard, Mark
Giever, Thomas
Hegeman, Robert N.
Pipp-Dahm, Michele
Cheng, Yee Chung
Lange, Carol
Jorns, Julie M.
Stella, Amy
Siddiqui, Nauman
Zurbriggen, Luke
Rajguru, Saurabh
Tarima, Sergey
Sriram, Deepika
Retseck, Janet
Rui, Hallgeir
Sahmoud, Tarek
Wisinski, Kari B.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT2-01-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-02
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Cheng, Chung Yee
    Chaudhary, Lubna N.
    Burfeind, John
    Retseck, Janet
    Tevaarwerk, Amye J.
    Burkard, Mark
    Paplomata, Elisavet
    Parkes, Amanda M.
    Jorns, Julie M.
    Tarima, Sergey
    Yee, Douglas
    Rui, Hallgeir
    Lange, Carol
    Sahmoud, Tarek
    Wisinski, Kari B.
    CANCER RESEARCH, 2022, 82 (04)
  • [2] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [3] A Phase II Trial of Onapristone and Fulvestrant for Patients With ER + and HER2-Metastatic Breast Cancer
    Kamaraju, Sailaja
    Fowler, Amy M.
    Tarima, Sergey
    Chaudhary, Lubna N.
    Burkard, Mark E.
    Giever, Thomas
    Cheng, Yee C.
    Parkes, Amanda
    Lange, Carol A.
    Pipp-Dahm, Michele
    Hegeman, Robert
    Siddiqui, Nauman
    Stella, Amy
    Rajguru, Saurabh
    Twaroski, Kyleigh
    Zurbriggen, Luke
    Jorns, Julie M.
    Rui, Hallgeir
    Keigley, Quinton J.
    Perlman, Scott B.
    Salem, Kelley
    Bradshaw, Tyler J.
    Sahmoud, Tarek
    Wisinski, Kari
    CLINICAL BREAST CANCER, 2025, 25 (03) : 251 - 260
  • [4] Effective sequence of endocrine therapy for ER-positive and HER2-negative metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Tashima, Rumiko
    Fujisue, Mamiko
    Nakano, Masahiro
    Toyozumi, Yasuo
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [6] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [7] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
  • [8] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [9] Efficacy of subsequent-abemaciclib treatment after disease progression on palbociclib combined with endocrine therapy in patients with ER-positive HER2-negative metastatic breast cancer
    Seki, Hirohito
    Nakai, Taketo
    Shimizu, Ken
    CANCER RESEARCH, 2023, 83 (05)
  • [10] Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
    Matikas, Alexios
    Foukakis, Theodoros
    Michalakis, Ilias
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 319 - 326
12345